JSR Corp v. Cytiva Bioprocess: Federal Circuit Splits Decision on Protein A Chromatography Patent
JSR Corporation and JSR Life Sciences brought an infringement appeal against Cytiva Bioprocess R&D AB over US10343142B2, covering a domain-C protein A chromatography ligand central to biopharmaceutical antibody purification. After 483 days of appellate proceedings, the Federal Circuit issued a split ruling — affirming in part and reversing in part — a mixed outcome with significant implications for both parties’ commercial positions.
A split Federal Circuit ruling on protein A affinity chromatography IP
JSR Corporation and its affiliate JSR Life Sciences, LLC filed this appeal on August 9, 2023 at the Court of Appeals for the Federal Circuit, challenging or defending a district court ruling involving US10343142B2. That patent claims a chromatography ligand comprising domain C from Staphylococcus aureus protein A — a foundational technology in the purification of monoclonal antibodies used in biopharmaceutical manufacturing. The defendant-appellee, Cytiva Bioprocess R&D AB, is a major supplier of bioprocess consumables, including protein A resin products sold under the MabSelect and related product lines.
The Federal Circuit resolved the case on December 4, 2024, issuing an order affirmed-in-part and reversed-in-part, with portions of the appeal also dismissed. This split outcome means that JSR prevailed on at least some of the issues raised, while Cytiva successfully defended other aspects of the lower court’s findings. The partial dismissal suggests certain claims or issues did not meet appellate threshold requirements — possibly for lack of standing or procedural deficiency on discrete sub-issues — without any merits adjudication on those portions.
The 483-day duration is broadly consistent with Federal Circuit timelines for biotechnology infringement appeals, which routinely involve complex claim construction and validity questions. The split disposition suggests neither party achieved a clean appellate victory, a pattern that often results in continued litigation on remand or renewed licensing negotiations. The public record does not disclose the specific claims affirmed versus reversed, nor whether the matter has been remanded to the district court, leaving important commercial uncertainties unresolved.
Filing to Appeal Dismissed in Part in 483 days
483 days at the Federal Circuit — consistent with the court’s typical 12–18 month appeal cycle for complex biotech IP disputes
Federal Circuit splits the decision: what affirmed-in-part and reversed-in-part means
What ‘affirmed-in-part, reversed-in-part’ means at the Federal Circuit
An affirmed-in-part, reversed-in-part ruling signals that the appellate court found no reversible error on some issues from the lower court, but identified legal error on at least one other issue. The court does not retry facts — it reviews claim construction de novo and factual determinations for clear error. A split disposition of this kind typically triggers a remand on the reversed portion, requiring further proceedings below. The partial dismissal of portions of the appeal indicates that certain issues were screened out on procedural grounds before any merits analysis.
Split appellate dispositionJSR’s partial win keeps some claims alive — but uncertainty persists
Where the Federal Circuit affirmed, JSR’s position from the district court stands — whether that represents a finding of infringement, validity, or another favourable ruling. Those affirmed holdings carry appellate authority and are substantially harder to re-litigate. However, on the reversed issues, JSR may face remand proceedings that could alter the overall outcome. The partial dismissal may also have narrowed the scope of relief JSR can ultimately obtain, leaving the patent’s commercial enforceability against Cytiva partially unresolved.
Partial enforceability retainedCytiva secures a reversal on at least one issue — meaningful but incomplete relief
On the issues where the Federal Circuit reversed, Cytiva has achieved a significant result — an appellate-level finding that the lower court erred. This may relate to claim scope, validity, or damages. However, because the ruling is only partial, Cytiva remains exposed on the affirmed issues. Unless the reversed portion is dispositive of the entire infringement claim, Cytiva likely faces continued proceedings on remand. Further certiorari to the Supreme Court remains theoretically available but statistically rare in biotech patent disputes.
Partial reversal — remand likelyProtein A chromatography IP landscape remains contested after this ruling
The split outcome provides neither side with the clean resolution that would typically clarify freedom-to-operate for the broader biopharmaceutical sector. Protein A affinity chromatography is a near-universal step in mAb manufacturing; the scope of domain-C ligand claims directly affects resin suppliers, contract manufacturing organisations, and biologic drug makers. Competitors and customers of both JSR and Cytiva should treat this ruling as a signal that US10343142B2 remains a live enforcement risk — particularly pending any remand proceedings — rather than a settled matter.
mAb purification sector risk elevatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | JSR Corporation | Company | Specialty materials and life sciences company — holder of US10343142B2Search in Eureka ↗ |
| Co-Plaintiff | Jsr Life Sciences, LLC | Company | Search in Eureka ↗ |
| Defendant | Cytiva Bioprocess R & D, AB | Individual | Cytiva Bioprocess R&D AB — global bioprocess consumables supplier, protein A resin productsSearch in Eureka ↗ |
| Plaintiff counsel | Naveen Modi | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Plaintiff law firm | Paul Hastings, LLP | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | David M. Krinsky | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Defendant law firm | Williams & Connolly LLP | Law Firm | Representing Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED-IN-PART AND REVERSED-IN-PART’ — reflects a nuanced appellate review rather than an outright win for either party. At the Federal Circuit, claim construction is reviewed de novo while underlying factual determinations are reviewed for clear error or substantial evidence depending on the finder of fact. A split disposition of this character suggests the court found at least one material legal error below while endorsing the remainder of the district court’s analysis. The partial dismissal indicates discrete procedural deficiencies on some issues, consistent with standing or finality objections. The commercial and legal stakes of each affirmed versus reversed issue will only be clear from the court’s written opinion.
US10343142B2 — Domain C protein A chromatography ligand for antibody isolation
US10343142B2, filed under application number US16/189894, protects a chromatography ligand comprising domain C derived from Staphylococcus aureus protein A, specifically engineered for antibody isolation. Protein A affinity chromatography is the dominant platform technology for purifying monoclonal antibodies in biopharmaceutical manufacturing, and the structural domain from which the ligand is derived directly determines binding affinity, alkaline stability, and resin lifetime. Domain-C-based ligands represent a specific engineered subset of protein A technology, distinguished from domain-B or multimodal ligand approaches used by competing products.
The strategic importance of US10343142B2 extends well beyond the direct dispute between JSR and Cytiva. Protein A resins are consumed at industrial scale by every major mAb manufacturer and contract development and manufacturing organisation globally. A valid and enforceable domain-C ligand patent creates licensing leverage across an entire supply chain segment. Given the high switching costs and regulatory revalidation burden associated with changing chromatography resins in a licensed biologic process, downstream customers also carry indirect exposure to any IP uncertainty in this space. Competing ligand developers — including those using engineered Z-domain or domain-B scaffolds — should map their designs against the claim scope of this patent.
Should you run an FTO analysis against US10343142B2?
Any organisation developing, supplying, or using protein A affinity chromatography resins — particularly those based on domain-C or structurally related ligands from Staphylococcus aureus protein A — faces direct exposure from US10343142B2. This includes resin manufacturers, ligand engineering companies, CDMOs, and mAb drug manufacturers whose processes rely on protein A capture steps. The Federal Circuit’s mixed ruling confirms the patent remains a live enforcement instrument. An FTO analysis is particularly urgent for companies considering new platform introductions or process changes that touch domain-C ligand chemistry.
PatSnap Eureka’s FTO Search Agent allows you to map your chromatography ligand technology against the claim tree of US10343142B2 in minutes. Eureka identifies structurally similar claims across the patent family, surfaces prior art that may bear on validity after the Federal Circuit’s remand, and flags continuation or divisional applications that could extend the enforcement perimeter. For R&D and regulatory teams planning resin qualification or substitution, Eureka’s landscape analysis provides the claim-level granularity needed to make defensible freedom-to-operate decisions before committing to a manufacturing platform.
Run a freedom-to-operate analysis on US10343142B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in protein A and bioprocess chromatography IP
Cases involving protein A chromatography ligand patents and affinity resin infringement at the Federal Circuit — mapped by claim type, validity basis, and outcome.
What this case signals for the bioprocess chromatography IP landscape
A Federal Circuit split on a protein A ligand patent is a rare signal — it tells the market this technology is genuinely contested at the highest level.
Protein A domain-C patents remain a live enforcement vector post-appeal
The Federal Circuit’s partial reversal does not extinguish US10343142B2 — it confirms the patent survived scrutiny on at least some claims. Any company supplying or using protein A resins incorporating domain-C ligands should treat this ruling as confirmation that JSR’s portfolio retains meaningful enforcement weight, and that freedom-to-operate analysis against this patent family is overdue.
Split dispositions often precede settlement or renewed licensing pressure
Historically, affirmed-in-part, reversed-in-part outcomes at the Federal Circuit create negotiating leverage for both parties — neither holds a clean hand. This dynamic frequently accelerates licensing negotiations or settlement, particularly where the underlying technology is commercially essential. Bioprocess suppliers and their customers should monitor any remand proceedings or licensing announcements closely.
JSR v Cytiva — key questions answered
The Federal Circuit issued an affirmed-in-part and reversed-in-part ruling on December 4, 2024, in case No. 23-2252. Portions of the appeal were also dismissed. This means JSR prevailed on some issues while Cytiva secured a reversal on at least one other issue. The specific claims or legal questions resolved in each direction are contained in the court’s written opinion.
US10343142B2 claims a chromatography ligand comprising domain C from Staphylococcus aureus protein A, designed for antibody isolation. Protein A affinity chromatography is the near-universal capture step in monoclonal antibody manufacturing. The patent’s domain-C specificity distinguishes it from ligands based on other protein A domains, making it directly relevant to a significant portion of commercial protein A resin products used globally in biopharmaceutical production.
At the Federal Circuit, an affirmed-in-part, reversed-in-part ruling means the lower court’s decision was upheld on some legal issues but found to contain reversible error on at least one other. The patent is not invalidated outright by this ruling. Depending on which issues were reversed — claim construction, validity, infringement, or damages — enforceability against Cytiva may be altered, and the case may be remanded for further proceedings consistent with the appellate ruling.
The partial dismissal noted in the basis of termination typically reflects procedural grounds such as lack of standing, mootness, or failure to meet finality requirements on discrete sub-issues. It does not represent a merits adjudication on those portions. The public record available in the docket entry does not specify which aspects of the appeal were dismissed or the precise procedural basis.
JSR Corporation and JSR Life Sciences, LLC were represented by Paul Hastings LLP, with Naveen Modi as lead attorney. Cytiva Bioprocess R&D AB was represented by Williams & Connolly LLP, with David M. Krinsky as lead attorney. Both firms have significant Federal Circuit patent litigation practices.
PatSnap Eureka searches patents and litigation data to answer instantly.